Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program.

Oliver IlliniHannah FabikanAurélie SwalduzAnders VikströmDagmar KrenbekMichael SchumacherElizabeth DudnikMichael StudnickaRonny ÖhmanRobert WurmLuciano WannessonNir PeledWaleed KianJair BarSameh DaherAlfredo AddeoOfer RotemGeorg PallAlona ZerAkram SaadTanja CuferHadas Gantz SorotskySayed M S HashemiKatja MohorcicRonen StoffYulia RovitskyShoshana Keren-RosenbergThomas WinderChristoph WeinlingerArschang ValipourMaximilian J Hochmair

Published in: Therapeutic advances in medical oncology (2022)

exon 14 skipping mutation, capmatinib showed durable systemic and intracranial efficacy and a manageable safety profile. This analysis confirms previously reported phase II data in a real-world setting.

Keyphrases

phase ii
clinical trial
open label
quality improvement
electronic health record
big data
tyrosine kinase
placebo controlled
randomized controlled trial
artificial intelligence
study protocol
data analysis